Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arecor Therapeutics PLC ( (GB:AREC) ) just unveiled an update.
Arecor Therapeutics has entered a co-development agreement with Sequel Med Tech to advance its ultra-concentrated insulin, AT278, in combination with Sequel’s advanced insulin delivery system. This partnership aims to address unmet needs in diabetes management and represents a strategic milestone for Arecor, enhancing its market positioning and extending its cash runway to 2027. Additionally, Arecor has secured up to $11 million in non-dilutive funding through a royalty financing agreement with Ligand Pharmaceuticals, which will support the development of AT278 and strengthen its financial stability.
The most recent analyst rating on (GB:AREC) stock is a Hold with a £68.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.
Spark’s Take on GB:AREC Stock
According to Spark, TipRanks’ AI Analyst, GB:AREC is a Neutral.
Arecor Therapeutics PLC’s stock is buoyed by strong technical indicators and positive corporate events, despite financial challenges typical of early-stage biotech companies. The technical analysis and corporate events significantly contribute to the overall score, highlighting market confidence and strategic growth initiatives.
To see Spark’s full report on GB:AREC stock, click here.
More about Arecor Therapeutics PLC
Arecor Therapeutics PLC is a biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases. The company specializes in creating transformative drug delivery solutions, with a particular emphasis on ultra-concentrated and ultra-rapid acting insulin products.
Average Trading Volume: 57,175
Technical Sentiment Signal: Hold
Current Market Cap: £27.37M
See more insights into AREC stock on TipRanks’ Stock Analysis page.